Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: A comparative study

Medicine

Volumn 80, Issue 1, 2001, Pages 54-73

  Pintado, Vicente ^a   MartÍn RabadÁn, Pablo ^a   Rivera, Mara Luisa ^a   Moreno, Santiago ^a   Bouza, Emilio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; PENTAMIDINE ISETHIONATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BONE MARROW BIOPSY; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPAIN; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LEISHMANIA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0035151414     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200101000-00006     Document Type: Article

References (164)

1. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary
2. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: A possible hazard for the host
3. Kala-azar in the adult. Apropos of 11 cases
4. Visceral leishmaniasis (kala-azar) complicating acute leukemia
5. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani
6. Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient
7. Duodenal leishmaniasis diagnosed by biopsy in two HIV-positive patients
8. Visceral leishmaniasis: Another HIVassociated opportunistic infection? Report of eight cases and review of literature
9. AIDS and Leishmania infantum. New approaches for a new epidemiological problem
10. Could infected drug-users be potential Leishmania infantum reservoirs?
11. Leishmania and human immunodeficiency virus coinfection: The first 10 years
12. Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients
13. European AIDS definition
14. Visceral leishmaniasis with partial response to ketoconazole in a patient with positive antibodies to the human immunodeficiency virus
15. Is leishmaniasis ever cured?
16. Leishmania donovani: An opportunistic microbe associated with progressive disease in three immunocompromised patients
17. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma
18. New perspectives on a subclinical form of visceral leishmaniasis
19. A prospective study of visceral leishmaniasis in an endemic area of Brazil
20. Leishmaniose cutanéo-muquense au cours de l'infection par le VIH
21. Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: Favourable course with itraconazole
22. Visceral leishmaniasis (Kala-azar) in transplant recipients
23. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV)
24. Ethiopian visceral leishmaniasis patients co-infected with human immunodeficiency virus
25. HIV viral load and response to antileishmanial chemotherapy in co-infected patients
26. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies
27. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the lest 10 years
28. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani
29. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV
30. La leishmaniosis en la España peninsular. Revisión histórico-bibliográfica (1912-1985)
31. Fatal leishmaniasis in renaltransplant patient
32. Leishmaniasis
33. Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies
34. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men
35. Visceral leishmaniasis in HIV infection. A totally opportunistic infection
36. Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment
37. The isolation of Leishmania donovani MON-18, from an AIDS patient in Portugal: Possible needle transmission
38. Treatment of HIV- 1associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy
39. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy
40. Laryngeal leishmaniasis as initial opportunistic disease in HIV infection
41. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
42. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
43. Acquired immunodeficiency syndrome-related visceral leishmaniasis presenting in a pleural effusion
44. PCR enzyme-linked immunosorbent assay for diagnosis of leishmaniasis in human immunodeficiency virus-infected patients
45. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial
46. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B
47. American cutaneous leishmaniasis due to Leishmania (Viannia) gnyanensis as an initial clinical presentation of human immunodeficiency virus infection
48. Diffuse cutaneous infection caused by a presumed monoxenous trypanosomatid in a patient infected with HIV
49. Clinical and evolutional characteristics of visceral leishmaniasis in HIV infected patients
50. Haemoculture as a tool for diagnosing visceral leishmaniasis in HIV-negative and HIV-positive patients: Interest for parasite identification
51. Visceral leishmaniasis in HIV-infected patients in the south of France
52. Human leishmaniases: Epidemiology and public health aspects
53. Global control and Leishmania HIV co-infection
54. Bone marrow changes at several stages of HIV infection, studied on bone marrow biopsies in 85 patients
55. Interstitial pneumonitis in human visceral leishmaniasis
56. Mucocutaneous leishmaniasis and AIDS: Case report
57. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
58. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: A study of 37 strains collected from patients with visceral leishmaniasis
59. Visceral leishmaniasis in immunocompromised hosts
60. Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users
61. Improvement of chronic diarrhea in patients with advanced HIV- 1 infection during potent antiretroviral therapy
62. Intestinal leishmaniasis in AIDS patients
63. Contribution of serological test to the diagnosis of visceral leishmaniasis in patients infected with the human immunodeficiency virus
64. Two cases of laryngeal leishmaniasis in patients infected with HIV
65. Visceral leishmaniasis in patients with AIDS: Report of three cases treated with pentavalent antimony and interferon-γ
66. Treatment of Mediterranean visceral leishmaniasis
67. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice
68. HIV-Leishmania co-infections in Italy: Serological data as an indication of the sequence of acquisition of the two infections
69. Epidemiological sur veillance of leishmaniasis in HIV-1-infected individuals in Italy
70. HIV-Leishmania co-infections in Italy. Isoenzyme characterization of Leishmania causing visceral leishmaniasis in HIV patients
71. Heterogeneity among zymodemes of Leishmania infantum from HIV-positive patients with visceral leishmaniasis in south Italy
72. Drug resistance in leishmaniasis: Its implication in systemic chemotherapy of cutaneous and mucocutaneous disease
73. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogiuconate
74. Hematologic manifestations of HIV infection
75. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies
76. Leishmaniasis in AIDS patients: Results of leukocytoconcentration, a fast biological method of diagnosis
77. Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in North Bihar, India
78. New Leishmania (Leishmania) infantum zymodemes responsible for visceral leishmaniasis in patients co-infected with HIV in Spain
79. HIV co-infection with a currently non-pathogenic flagellate
80. Serodiagnosis of leishmaniasis
81. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
82. Visceral leishmaniosis in HIV-positive patients: Primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts
83. Maintenance itraconazole for visceral leishmaniasis in HIV infection
84. Visceral leishmaniasis in patients infected with the human immunodeficiency virus
85. Prevalence of gastrointestinal leishmaniasis in Spanish HIV-positive patients with digestive symptoms
86. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
87. Assessment of anopurinol plus meglumine antimoniate in the treatment of visceral leshmaniasis in patients infected with HIV
88. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus
89. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome
90. Interferon-γ associated with conventional therapy for recurrent visceral leishmaniasis in a patient with AIDS
91. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency ,virus-infected patients
92. Clinico-epidemiological characteristics, prognostic factors and survival analysis of patients coinfected with HIV and Leishmania in an area of Madrid, Spain
93. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: Report of two cases
94. Treatment of visceral leishmaniasis in a patient with AIDS with antimony and γ-interferon: Remission and prevention of relapse by maintenance therapy with weekly pentamidine
95. Fatal leishmaniasis in renal-transplant recipient
96. Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: A case report
97. Kalaazar in a hospital for infectious diseases. Review of 104 cases
98. Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears
99. Western blot analysis of antibodies to Leishmania infantum antigens: Potential role of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes
100. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection
101. Visceral leishmaniasis and HIV infection: Unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis
102. Visceral leishmaniasis following treatment with liposomal amphotericin B
103. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type- 1
104. Visceral leishmaniasis in HIV-l-infected individuals: A common opportunistic infection in Spain?
105. An easy and quick method for the diagnosis of visceral leishmaniasis in HIV-linfected individuals
106. Fever of uncertain origin in patients infected with the human immunodeficiency virus
107. Amphotericin B for second line treatment of Indian kala-azar
108. Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus
109. Infection of sand flies by humans coinfected with Leishmania infantum and human immunodeficiency virus
110. Atypical leishmaniasis in a patient infected with human immunodeficiency virus
111. Visceral leishmaniasis in patients infected with human imununodeficiency virus
112. Visceral leishmaniasis (kalaazar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain
113. Jejunal function and pathology in visceral leishmaniasis
114. Pleural and peritoneal leishmaniasis in an AIDS patient
115. Isolated laryngeal leishmaniasis in an immunocompetent patient: Successful treatment with surgery
116. Comparison of the indirect immunofluorescent antibody test and the direct agglutination test for serodiagnosis of visceral leishmaniasis in HIV-infected subjects
117. Secondary prophylaxis for Leishmania infection in an HIV-positive patient
118. Parasite genotypically related to a monoxenous trypanosomatid of dog's flea causing opportunistic infection in an HIV positive patient
119. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
120. Clinical spectrum of leishmaniasis
121. Polyarthritis caused by Leishmania in a patient with AIDS
122. Visceral leishmaniasis in HIV infection and AIDS: Clinical features and response to therapy
123. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-infected patients
124. Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients
125. Interest and reliability of a polymerase chain reaction on bone-marrow samples in the diagnosis of visceral leishmaniasis in AIDS
126. Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain
127. Frequency of subclinical visceral leishmaniasis in HIVinfected patients in Spain
128. Neoplasms associated with human immunodefciency virus infection. Study of the clinical course of 70 patients
129. The interaction of opportunistic infections and HIV replication
130. Leishmania-human immunodeficiency virus coinfection in the Mediterranean basin: Isoenzymatic characterization of 100 isolates of the Leishmania infantum complex
131. Immunological findings in HIV-Leishmania coinfection
132. Use of an Itraconazole/A 1lopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS
133. Visceral leishmaniasis in immunocompromised patients
134. Leishmaniose visceral fatal associada a sindrome de imunodeficiencia adquirida: Relato de caso corn achados necroscopicos e estudo imuno-histoquimico
135. Visceral leishmaniasis: Comparative study in patients with and without HIV infection
136. Visceral leishmaniasis in patients with HIV infection
137. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients
138. Leishmania in bronchoalveolar lavage
139. Visceral leishmaniasis and HIV-1 co-infection in southern France
140. Rectal leishmaniasis in a patient with acquired immunodeficiency syndrome
141. Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)
142. Visceral leishmaniasis in HIV-infected patients
143. Pathophysiology and management of HIV-associated hematologic disorders
144. Longer-term immunologic effects and side effects of successful antiretroviral therapy
145. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom
146. Effect of HAART on natural history of AIDS-related opportunistic disorders
147. Immunology of AIDS and HIV infection
148. Prophylaxis and treatment of opportunistic infection in patients on HAART
149. Comparison of regimes of treatment of antimony-resistant kala-azar patients: A randomized study
150. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus
151. Leishmania and the pathogenesis of HIV infection
152. Glucantime-resistant visceral leishmaniasis in immunocompromised patients
153. Leishmania esophagitis in an AIDS patient: An unusual form of visceral leishmaniasis
154. Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication
155. Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells
156. Central nervous system toxoplasmosis in homosexual men and parenteral drug abusers
157. Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases
158. Leishmania/HIV co-infection, south-western Europe, 1999- 1998. Retrospective analysis of 965 cases